Related Experiment Video
Updated: Sep 8, 2025
Coculture Assays to Study Macrophage and Microglia Stimulation of Glioblastoma Invasion
Published on: October 20, 2016
Nanoparticle-Mediated CXCL12-CXCR4 Inhibition Reprograms Macrophages and Suppresses Gastric Carcinoma
Qianqian Cao1, Xiaolei Cheng2, Rongbin Lv3
1Cancer Center, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250033, P. R. China.
Abstract:
Gastric carcinoma (GC) remains a major global health challenge, requiring novel therapeutic approaches. This study investigates the efficacy of self-assembled M2pep-Cs NPs/Plerixafor nanoparticles in suppressing GC by targeting the CXCL12-CXCR4 signaling pathway and reprogramming tumor-associated macrophages (TAMs) to enhance anti-tumor immunity. The nanoparticles' physicochemical properties and biocompatibility are assessed using transmission electron microscopy, dynamic light scattering, and biological assays. A GC mouse model is established, followed by histological and immunohistochemical analyses to evaluate tumor apoptosis and proliferation. Multi-omics approaches, including transcriptomics, proteomics, and metabolomics, identify key genes and pathways affected by treatment. Flow cytometry and ELISA quantify immune activation markers; while, cell migration and invasion assays evaluate tumor suppression effects. The results demonstrate that M2pep-Cs NPs/Plerixafor effectively modulates the tumor microenvironment, suppressing GC progression by reprogramming TAMs through CXCL12-CXCR4 inhibition, enhancing immune recognition and T cell responses. This study provides mechanistic insights and highlights the potential of nanoparticle-based immunotherapy for GC, offering a promising avenue for clinical translation.
Insights
Novel nanoparticles effectively suppress gastric cancer (GC) by reprogramming tumor-associated macrophages (TAMs) and inhibiting the CXCL12-CXCR4 pathway, boosting anti-tumor immunity for potential clinical translation.
Area of Science:
- Oncology
- Immunology
- Nanotechnology
Background:
- Gastric carcinoma (GC) presents a significant global health challenge.
- Novel therapeutic strategies are crucial for effective GC treatment.
- Targeting the tumor microenvironment and immune system offers a promising approach.
Purpose of the Study:
- To investigate the efficacy of M2pep-Cs NPs/Plerixafor nanoparticles in suppressing GC.
- To explore the mechanism of action involving the CXCL12-CXCR4 signaling pathway and tumor-associated macrophages (TAMs).
- To assess the potential for enhancing anti-tumor immunity.
Main Methods:
- Characterization of nanoparticle physicochemical properties and biocompatibility.
- Establishment of a GC mouse model with histological and immunohistochemical analyses.
- Multi-omics approaches (transcriptomics, proteomics, metabolomics) and immunological assays (flow cytometry, ELISA).
Main Results:
- M2pep-Cs NPs/Plerixafor nanoparticles demonstrated effective suppression of GC progression in a mouse model.
- Treatment reprogrammed TAMs by inhibiting the CXCL12-CXCR4 pathway, modulating the tumor microenvironment.
- Enhanced immune recognition and T cell responses were observed, indicating boosted anti-tumor immunity.
Conclusions:
- M2pep-Cs NPs/Plerixafor nanoparticles show significant potential as an immunotherapy for gastric cancer.
- The study provides mechanistic insights into nanoparticle-mediated immune reprogramming.
- This approach offers a promising avenue for clinical translation in GC treatment.
